Phase-III of clinical trials of a Chinese Coronavirus candidate vaccine will be organized in Pakistan later this month.
It has been revealed by the Parliamentary Secretary, National Health Services Regulations and Coordination, Nausheen Hamid.
According to details, China National Pharmaceutical Group (Sinopharm) has developed the inactivated COVID-19 vaccine, Phase-I and –II clinical trials of which have already been successfully concluded in China.
On 15 September, Sinopharm will supply the Coronavirus vaccine to the National Institute of Health (NIH) for Phase-III clinical trials which will start from 20 September.
In this regard, healthcare specialists linked with NIH are being provided with proper training.
Sinopharm is carrying out Phase-III clinical trials simultaneously in several countries because the number of active Coronavirus cases in China is simply insufficient to comprehensively assess the vaccine.
The Parliamentary Secretary said that Pakistan has been closely working with China during the Coronavirus pandemic, adding that Phase-III clinical trials of Sinopharm’s vaccine will also reach a successful conclusion.